This enduring monograph provides pharmacists with an evidence-based review of gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging, with emphasis on differences in relaxivity, dosing, safety profiles, and clinical performance. The activity supports pharmacists involved in formulary management and medication safety by highlighting how contrast agent selection can impact diagnostic quality, patient exposure to gadolinium, and overall value of care.
At the completion of this activity, the participant will be able to:
- Describe the key differences among gadolinium-based contrast agents (GBCAs), including molecular structure, relaxivity, dosing, and safety profiles that influence MRI diagnostic performance.
- Explain how GBCA selection impacts patient safety, including considerations related to gadolinium exposure, renal function, and use in patients requiring repeated contrast-enhanced MRI examinations.
- Discuss the role of the pharmacist in evaluating MRI contrast agents for formulary inclusion, including considerations of efficacy, safety, sustainability, and overall value within health-system practice.
The content of this CEÂ webinar is intended for Technologists, Imaging Nurses, Administrators, Researchers, and other healthcare professionals.
This program has been approved for 1.0 hour of Category A CE credit as designated by the Society for MR Radiographers & Technologists (SMRT) RCEEM. Additionally, this activity may be available in multiple formats or from different sponsors. ARRT regulations state that an individual may not repeat an activity for credit if it was reported in the same or any subsequent biennium.
Release Date: 01/23/2026 | Expires 01/23/2027
Faculty and Planner Disclosures:
As an accredited provider of continuing medical education, it is the policy of Northwest Imaging Forums, Inc. (NWIF) to ensure balance, independence, objectivity, and scientific rigor in all of its activities. In accordance with this policy, faculty and planners must disclose all relevant financial relationships with ineligible companies. Any relevant financial relationships have been mitigated by NWIF to ensure the integrity of the CME activity. The planner has nothing to disclose.
